Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including inflammatory, immune-mediated, and/or chronic inflammatory gastrointestinal diseases; systemic immune-mediated diseases; cancers; and infectious diseases.

The present invention encompasses compounds of formula (I) ##STR00001##
wherein the groups R.sup.1 to R.sup.4 and X.sup.1 to X.sup.5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

The present invention encompasses compounds of formula (I) ##STR00001##
wherein the groups R.sup.1 to R.sup.4 and X.sup.1 to X.sup.5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

The present invention relates to a donepezil derivative of general formula (I) or a pharmaceutically acceptable salt thereof, wherein R in the formula is as disclosed herein; and a method for preparation thereof; and a composition comprising an effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in preparing a medicament for treating a disease resulted from an abnormality in acetylcholinesterase activity. ##STR00001##

The present invention encompasses compounds of formula (I)

##STR00001##

wherein the groups R.sup.1 to R.sup.4 and X.sup.1 to X.sup.5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

The present invention encompasses compounds of formula (I)

##STR00001##

wherein the groups R.sup.1 to R.sup.4 and X.sup.1 to X.sup.5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

The present invention relates to new arylaminoalcohol derivatives of formula (I), and to a method for the preparation of such compounds: I The invention also relates to the use of these compounds as medicaments, and in particular for the prevention and/or the treatment of parasitic diseases caused by apicomplexan parasites such as malaria and toxoplasmosis. Finally, the invention relates to pharmaceutical compositions containing such compounds of formula (I) as active principles. ##STR00001##

The invention relates to the field of preserving the viability of organs or tissues to be transplanted into a recipient in need of such a transplantation. In particular, the invention relates to use of a sigma 1 receptor agonist compound in preservation solutions and preservation solutions comprising a sigma 1 receptor agonist compound.

The invention relates to the field of preserving the viability of organs or tissues to be transplanted into a recipient in need of such a transplantation. In particular, the invention relates to use of a sigma 1 receptor agonist compound in preservation solutions and preservation solutions comprising a sigma 1 receptor agonist compound.

A series of sofalcone derivatives having the effect of inhibiting platelet aggregation and antithrombotic effect are disclosed. These sofalcone derivatives are antagonists of TxA2 receptor and have the effect of inhibiting platelet activation and aggregation without causing bleeding. In addition, a preparing method of the sofalcone derivatives and a method for preventing or treating thrombotic diseases or inhibiting platelet aggregation by administrating the sofalcone derivatives are also disclosed.